nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
BDNF has also been implicated in a plethora of neurological disorders.
|
31532010 |
2020 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, inhibition of SHIP2 appears to be valuable therapeutic strategy against neurological disorders associated with insufficient BDNF functions.
|
30753865 |
2019 |
nervous system disorder
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Finally, high throughput sequencing data from different brain regions and neurological disorders were analyzed to measure correlation of candidate miRNAs with BDNF level in experimental studies.
|
31751881 |
2019 |
nervous system disorder
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, we proved the neurogenic potential of several hb-HDACis, alongside their ability to enhance <i>BDNF</i> expression, which by modulating the neurogenesis and/or compensating for neuronal loss, could be propitious for treatment of neurological disorders.
|
30841499 |
2019 |
nervous system disorder
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The significant positive impact of curcumin supplementation on BDNF levels indicates its potential use for neurological disorders that are associated with low BDNF levels.
|
31279955 |
2019 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
When compared with GB treatment, GK treatment maintained high levels of phosphoinositide 3‑kinase/phosphorylated‑protein kinase B expression, and induced a marked upregulation of Wnt family member 1 and brain derived neurotrophic factor, indicating that GK, as a natural plant compound, may have more attractive prospects for clinical application in the treatment of neurological disorders than GB.
|
30221704 |
2018 |
nervous system disorder
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Accumulating evidence suggests that a decrease in brain-derived neurotrophic factor (BDNF) level induces a variety of psychiatric and neurological disorders.
|
29540150 |
2018 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
The presence of neurotrophin receptors in the HUCB CD45<sup>+</sup> pan-hematopoietic subpopulation may explain the neuroprotective effect of cord blood in therapy of a variety of neurological disorders.
|
29274773 |
2018 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
<i>α</i>-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor (AMPA-R) potentiators with brain-derived neurotrophic factor (BDNF)-induction potential could be promising as therapeutic drugs for neuropsychiatric and neurologic disorders.
|
29298820 |
2018 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Novel BDNF-focused interventions are being developed for obesity, diabetes and neurological disorders.
|
29217485 |
2018 |
nervous system disorder
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Multiple BDNF transcripts have distinct functional properties and epigenetic modulation of BDNF gene transcription is implicated in the neurological disorders.
|
29305263 |
2018 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Brain-derived neurotrophic factor (<i>Bdnf</i>) has been implicated in several neurological disorders including Rett syndrome (RTT), an X-linked neurodevelopmental disorder caused by loss-of-function mutations in the transcriptional modulator methyl-CpG-binding protein 2 <i>(MECP2)</i>.
|
28751857 |
2017 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
The Effect of Aerobic Exercise on Brain-Derived Neurotrophic Factor in People with Neurological Disorders: A Systematic Review and Meta-Analysis.
|
29057125 |
2017 |
nervous system disorder
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Thus, understanding the epigenetic regulation at the BDNF promoters will shed light on future therapies for neurological disorders.
|
28272318 |
2017 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Bone marrow-derived mesenchymal stem cells (BMMSCs) may provide a potential cell-based therapy against neurologic disorders through induction of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF).
|
28492549 |
2017 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family critical for neuronal cell survival and differentiation, with therapeutic potential for the treatment of neurological disorders and spinal cord injuries.
|
28466111 |
2017 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Brain-derived neurotrophic factor (BDNF) exerts substantial protective effects for neurological disorders.
|
28243312 |
2017 |
nervous system disorder
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Serum BDNF levels were analyzed by ELISA kit in 378 subjects: 134 Alzheimer's disease (AD) patients, 115 amnestic mild cognitive impairment (MCI) patients, and 129 controls divided into two groups: neurodegenerative control group (ND), consisting of 49 Parkinson's disease patients without any cognitive complaints, and cognitively normal control group (CN), consisting of 80 subjects without any neurological disorders.
|
28341039 |
2017 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuregulin 3 (NRG3), a brain-enriched neurotrophin, undergoes alternative splicing and is implicated in several neurological disorders with developmental origins.
|
27771971 |
2017 |
nervous system disorder
|
0.400 |
GeneticVariation
|
group |
BEFREE |
An optimised liposomal formulation [DPPC/P-lyso-PC/DSPE-PEG2000 90/10/4 (mol/mol) (LTSL)] was chosen for further application in encapsulating therapeutic proteins, such as lysozyme and the brain-derived neurotrophic factor (BDNF), which are recognized as drug carriers and potential therapeutic agents for kidney diseases and neurological disorders.
|
28377318 |
2017 |
nervous system disorder
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Various studies suggested that brain-derived neurotrophic factor (BDNF) gene polymorphisms contributed to the development of many neurological disorders.
|
26000807 |
2016 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
The mean value for urinary extracellular neurotrophin receptor p75 from 28 amyotrophic lateral sclerosis patients measured by ELISA was 7.9±0.5 ng/mg creatinine and this was significantly higher (p<0.001) than 12 controls (2.6±0.2 ng/mg creatinine) and 19 patients with other neurological disease (Parkinson's disease and Multiple Sclerosis; 4.1±0.2 ng/mg creatinine).
|
24475283 |
2014 |
nervous system disorder
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Accumulating evidence suggests that alterations in BDNF expression levels underlie a variety of psychiatric and neurological disorders.
|
25223903 |
2014 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Brain-derived neurotrophic factor (BDNF) has been implicated in the pathophysiology of psychiatric and neurological disorders and in the mechanisms of antidepressant pharmacotherapy.
|
23253771 |
2013 |
nervous system disorder
|
0.400 |
Biomarker
|
group |
BEFREE |
Decreased expression of neuronal genes such as brain-derived neurotrophic factor (BDNF) is associated with several neurological disorders.
|
23712629 |
2013 |